A cross-sectional sero-survey on preoperative HBV vaccination policy in Poland
Open Access
- 25 July 2017
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 515
Abstract
A two-dose preoperative vaccination schedule against HBV has been the widely accepted policy in Poland. However, its effectiveness has not yet been assessed. Objective: To evaluate a two-dose preoperative HBV vaccination policy by an assessment of the proportion of patients who don’t present a protective level of anti-HBs (180 days after. Anti-HBs titer was below a protective level in 49.2% of participants (0.0 mIU/ml in 17.8%, 0.1–9.9 mIU/ml in 31.4%); none of them were aware of this fact. Age ≤ 52 years (OR = 1.89) and having surgery more than 37.5 days after HBV vaccination (OR = 2.70) were associated with greater odds of being protected against HBV infection through vaccination. For the time frame between the second dose implementation and surgery 23 days, a sensitivity of 84% and specificity of 22% for obtaining protection against HBV infection was found, for the time frame >37.5 days – sensitivity remained high (80%), while specificity increased (41%); there was an apparent peek on the ROC curve between 38 and 60 day. In the group vaccinated 0–37.5 days before surgery, less patients had the protective level of anti-HBs titer than in vaccinated 38–60 days before surgery (32.3% vs 60.0%; p = 0.03). The success rate in achieving adequate immune protection with two dose HBV vaccination schedule in preoperatively vaccinated patients is relatively low, especially among those vaccinated less than five weeks prior to surgery. In more than a third of cases the standard three-dose regimen could have been implemented, as participants had time to complete a third dose. Current recommendations regarding a preoperative policy with a 2-dose vaccination schedule in Poland should be revised; the best time to perform surgery after the implementation of the second dose of vaccine in the context of patient protection against HBV infection would be between 38 and 60 days.Keywords
Funding Information
- Pomorski Uniwersytet Medyczny (WNoZ-303-02/S/10, WNoZ-303-02/S/11.)
This publication has 31 references indexed in Scilit:
- Seroprevalence of hepatitis B and immune response to hepatitis B vaccination in Chinese college students mainly from the rural areas of western China and born before HBV vaccination integrated into expanded program of immunizationHuman Vaccines & Immunotherapeutics, 2013
- Long‐term efficacy of the hepatitis B Vaccine in a high‐risk groupJournal of Medical Virology, 2013
- Hepatitis B: Epidemiology and prevention in developing countriesWorld Journal of Hepatology, 2012
- The worldwide impact of vaccination on the control and protection of viral hepatitis BDigestive and Liver Disease, 2011
- Chronic hepatitis B virus infection and rubella susceptibility in pregnant womenJournal of Viral Hepatitis, 2009
- Preoperative vaccination for HBV at Polish hospitals as a possible public health tool to limit the spread of the epidemic: A cross-sectional studyVaccine, 2009
- Viral hepatitis in Germany: poor vaccination coverage and little knowledge about transmission in target groupsBMC Public Health, 2008
- Evaluation of immune response to Hepatitis B vaccine in health care workers at a tertiary care hospital in Pakistan: an observational prospective studyBMC Infectious Diseases, 2007
- Hepatitis B epidemiology in Poland, Central and Eastern Europe and the Newly Independent StatesVaccine, 2000
- A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis BClinical and Experimental Immunology, 1999